Patients with locally advanced dMMR colon cancer received ipilimumab on Day 1 and nivolumab on Day 1+15, followed by surgery within 6 weeks. The study had two independent primary endpoints: safety and 3-year DFS. ...
参考文献 Chalabi M, et al. Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study. ESMO Congress 2022, LBA7 Presidential Symposium II, 11.09.2022, h. 16:30 – 18:15,...
In order to combat this limitation several chemotherapeutic regimens are now being combined with targeted therapies after the knowledge acquired on the inevitable effects of the tumor microenvironment on the colon cancer growth and progress. The colon tumor niche mainly consists of a large mass of ...
High recurrence and metastasis rates and poor prognoses are the major challenges of current cancer therapy. Mounting evidence suggests that cancer stem cells (CSCs) play an important role in cancer development, chemoradiotherapy resistance, recurrence, a
OBJECTIVE: In this review we highlight the need to expand the scope of environ-mental health research, which now focuses largely on the study of toxicants, to incorporate infectious agents. We provide evidence that environmental health research would be strengthened through finding common ground with...
NETs formed through the stimulation of primary tumours can act as scaffolds for circulating tumour cells, providing a favourable environment for their colonization and growth, and this particular role has been confirmed in the omental metastasis of ovarian cancer and liver metastasis of colon cancer [...
12 The medical relevance of perturbations in this system was demonstrated more than 25 years ago through the identification of the gene mutated in patients with familial adenomatous polyposis, an inherited cancer predisposition syndrome.13, 14 The gene, termed APC, encodes a large protein that ...
Further studies with large sample size remain warranted to analyze the potential molecular mechanisms of specific tetraspanins regulating ADAM17 assembly in colon cancer cells. In this study, we conducted experimental analyses on another important metastasis-associated member of the ADAM family, ADAM10 [...
Bazedoxifene as a novel GP130 inhibitor for colon cancer therapy. J. Exp. Clin. Cancer Res. CR 38, 63 (2019). Article PubMed Google Scholar Wu, X., Cao, Y., Xiao, H., Li, C. & Lin, J. Bazedoxifene as a novel GP130 inhibitor for pancreatic cancer therapy. Mol. Cancer Ther....
2024年欧洲肿瘤内科学会(ESMO)年会于9月13-17日在西班牙·巴塞罗那召开,荷兰癌症研究所的Peter de Gooyer博士报告了NICHE-3研究,探索了Nivolumab联合Relatlimab用于dMMR结直肠癌新辅助治疗(英文标题:Neoadjuvant Nivolumab plus Relatlimab...